Imatinib Stada

Imatinib, the active ingredient in Imatinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets the BCR‑ABL fusion protein that drives malignant cell proliferation and is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, adhering to EU quality standards and providing reliable global distribution.

Imatinib acts on the BCR‑ABL tyrosine kinase pathway and is used in specific hematologic and solid‑tumor indications. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves durable molecular remission. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth in patients with KIT or PDGFRA mutations. - Philadelphia‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: generalized tiredness affecting daily activities. - Diarrhea: loose stools that may be intermittent.

Serious or Rare Side Effects: - Neutropenia: significant reduction in neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or clinical hepatitis. - Cardiac failure: signs of reduced cardiac output, especially in patients with pre‑existing heart disease.

When prescribing Imatinib, clinicians should observe several precautionary measures to minimize risk. - Monitor blood counts: perform regular complete blood count tests to detect cytopenias. - Assess liver function: check hepatic enzymes before and during therapy. - Evaluate cardiac status: perform baseline ECG and monitor for heart‑failure signs. - Avoid strong CYP3A4 inhibitors: review concomitant medications that may increase exposure. - Counsel on pregnancy: discuss potential risks and advise effective contraception. - Store at room temperature: keep in original container, protect from moisture and light.

Imatinib interacts with several drugs that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise imatinib levels and risk toxicity. - CYP3A4 inducers (e.g., rifampicin, St. John's wort): can lower exposure and reduce efficacy. - Concomitant use with warfarin: may enhance anticoagulant effect and require close INR monitoring.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect gastric pH and modestly reduce absorption. - Diuretics (e.g., furosemide): can increase risk of fluid retention and edema. - Live attenuated vaccines: potential for reduced immune response; schedule appropriately.